# Chronic Kidney Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-kidney-disease

> 2 upcoming FDA catalysts in chronic Kidney Disease: elecoglipron (AZN) on Oct 2030 to Jan 2031 (topline data readout); elecoglipron (AZN) on October 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 9, 2025 | [ASTRAZENECA PLC primary completion](https://sec-api.dev/companies/azn/catalysts) | AZN | Chronic Kidney Disease | completed | "NCT06350123 (Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-06-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350123)) |
| June 26, 2026 | [ASTRAZENECA PLC topline data readout](https://sec-api.dev/companies/azn/catalysts) | AZN | Chronic Kidney Disease | completed | "NCT06350123 (Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-09 (ACTUAL); Lead Sponsor AstraZeneca; Results First Posted 2026-06-26." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350123?tab=results)) |
| September 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease | delayed | "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717698)) |
| Sep to Dec 2026 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Chronic Kidney Disease | scheduled | "NCT06717698 (A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717698)) |
| Oct 2030 to Jan 2031 | [Elecoglipron topline data readout](https://sec-api.dev/pdufa/elecoglipron) | AZN | Chronic Kidney Disease | scheduled | "NCT07753993 (A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07753993)) |
| October 2030 | [Elecoglipron primary completion](https://sec-api.dev/pdufa/elecoglipron) | AZN | Chronic Kidney Disease | scheduled | "NCT07753993 (A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-10-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07753993)) |

## Drugs

- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Elecoglipron](https://sec-api.dev/pdufa/elecoglipron) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-kidney-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Kidney Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-kidney-disease

```bibtex
@misc{secapidev_indications_chronic_kidney_disease_20261116,
  title        = {Chronic Kidney Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-kidney-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_kidney_disease_20261116","title":"Chronic Kidney Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-kidney-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
